Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 14, 2018

SELL
$207.3 - $300.31 $2.59 Million - $3.75 Million
-12,499 Reduced 47.17%
14,000 $3 Million
Q2 2018

Aug 14, 2018

BUY
$101.55 - $313.9 $863,073 - $2.67 Million
8,499 Added 47.22%
26,499 $7.41 Million
Q1 2018

May 15, 2018

BUY
$93.35 - $149.04 $1.68 Million - $2.68 Million
18,000 New
18,000 $2.1 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.35B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Atika Capital Management LLC Portfolio

Follow Atika Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Atika Capital Management LLC with notifications on news.